AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38043911 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg, twice daily)
Number of subjects: 159
Study 38043911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 38043911 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 159
Study 38044204 — intervention group
Group type: EXPERIMENTAL
Intervention: givosiran 2.5 mg/kg
Number of subjects: 7
Study 38044204 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 38044272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride 1.25% (pilo)
Number of subjects: 43
Study 38044272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 38044419 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg eliapixant
Number of subjects: 6
Study 38044439 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-ECGI using the reusable, washable vest
Number of subjects: 77
Study 38044439 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR-ECGI
Number of subjects: 77
Study 38044460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) Tranexamic acid (TXA)
Number of subjects: 0
Study 38044460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) Tranexamic acid (TXA)
Number of subjects: 0
Study 38044460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38045112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension focused ECHO program for Community Health Extension Workers (CHEWs)
Number of subjects: 42
Study 38045112 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies for implementing the ECHO program
Number of subjects: 42
Study 38045238 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncuria BC multiplex immunoassay
Number of subjects: 36
Study 38045245 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigational bronchoscopy with integrated digital tomosynthesis
Number of subjects: 0
Study 38045245 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography-guided transthoracic needle biopsy (CT-TTNB)
Number of subjects: 0
Study 38045318 — intervention group
Group type: EXPERIMENTAL
Intervention: WFPB dietary intervention
Number of subjects: 31
Study 38045318 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study 38045387 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 vaccine
Number of subjects: 1500
Study 38045434 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Boosting Classifier (GBC) model
Number of subjects: 35389
Study 38045440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine serially measured proteins
Number of subjects: 382
Study 38045443 — intervention group
Group type: EXPERIMENTAL
Intervention: Visitation policies and ward structure changes during COVID-19
Number of subjects: 616
Study 38045443 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient characteristics (age, sex, race/ethnicity, admission type, discharge destination)
Number of subjects: 616
Study 38045443 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant interviews
Number of subjects: 616
Study 38045523 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion
Number of subjects: 0
Study 38045523 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38045525 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Decontamination of the Digestive Tract
Number of subjects: 0
Study 38045525 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 38045529 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategy package (video education, HIV self-testing, and co-location)
Number of subjects: 0
Study 38045529 — intervention group
Group type: COMPARATOR
Intervention: Comparison facilities (no strategies implemented)
Number of subjects: 0
Study 38045767 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic complete posterior knee capsulotomy
Number of subjects: 15
Study 38045774 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power thulium laser enucleation of prostates (ThuLEP)
Number of subjects: 80
Study 38045803 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly BUP-XR (Sublocade;® two injections of 300 mg, then four maintenance injections of 100 mg or 300 mg) for 24 weeks
Number of subjects: 314
Study 38045803 — intervention group
Group type: COMPARATOR
Intervention: Daily standard-of-care (SoC) medication (liquid methadone 60-120 mg or sublingual/transmucosal buprenorphine 8-24 mg) for 24 weeks
Number of subjects: 314
Study 38045803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of BUP-XR versus SoC
Number of subjects: 314
Study 38045803 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR among participants rated more severe at study baseline
Number of subjects: 314
Study 38045803 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP-XR among participants in maintenance treatment for more than 28 days
Number of subjects: 314
Study 38046041 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) treatment for HCV-viremic patients, with 152 patients linked to care and treated.
Number of subjects: 2336
Study 38046041 — intervention group
Group type: EXPERIMENTAL
Intervention: Link-to-care project for HCV treatment.
Number of subjects: 2336
Study 38046050 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based conversational engagement clinical trial (I-CONECT)
Number of subjects: 39
Study 38046050 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice recruitment strategies
Number of subjects: 39
Study 38046050 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment criteria adjustments
Number of subjects: 39
Study 38046050 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenges in recruitment
Number of subjects: 39
Study 38046050 — intervention group
Group type: COMPARATOR
Intervention: Comparison with White participants
Number of subjects: 39
Study 38046082 — intervention group
Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy
Number of subjects: 0
Study 38046082 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 38046085 — intervention group
Group type: EXPERIMENTAL
Intervention: Early activity and mobilization
Number of subjects: 0
Study 38046085 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 38046113 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 81
Study 38046113 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 81
Study 38046145 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier dressing (adhesive material applied to the skin)
Number of subjects: 0
Study 38046145 — intervention group
Group type: COMPARATOR
Intervention: No barrier dressing (control group)
Number of subjects: 0
Study 38046376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ramucirumab
Number of subjects: 34
Study 38046390 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38046409 — intervention group
Group type: EXPERIMENTAL
Intervention: AIaMD assessment of dermoscopic images
Number of subjects: 268
Study 38046686 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Therapeutic Mild Hypercapnia
Number of subjects: 0
Study 38046686 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 38046839 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal catheter therapy
Number of subjects: 0
Study 38046839 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive positive pressure ventilation
Number of subjects: 0
Study 38046911 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 13026
Study 38046911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13026
Study 38046912 — intervention group
Group type: EXPERIMENTAL
Intervention: F&V + Cook (cooking instructions)
Number of subjects: 142
Study 38046912 — intervention group
Group type: COMPARATOR
Intervention: F&V Only (no cooking instructions)
Number of subjects: 142
Study 38046981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 µg administered via dry powder inhaler, single and multiple (twice daily) doses.
Number of subjects: 20
Study 38047142 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.10 mg/kg to 0.20 mg/kg)
Number of subjects: 0
Study 38047142 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 38047249 — intervention group
Group type: EXPERIMENTAL
Intervention: SNG100 cream (hydrocortisone 1% in a cream base with sulphated polysaccharide), applied twice daily for 14 days
Number of subjects: 60
Study 38047249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% cream, applied once daily for 14 days
Number of subjects: 60
Study 38047249 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% cream, applied twice daily for 14 days
Number of subjects: 60
Study 38047249 — intervention group
Group type: EXPERIMENTAL
Intervention: SNG100 cream
Number of subjects: 60
Study 38047365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Shared Decision-Making Model (CBSDM)
Number of subjects: 18
Study 38047365 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 18
Study 38047535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Biopsy Calcitonin Measurements
Number of subjects: 0
Study 38047535 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38047967 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep diary
Number of subjects: 120
Study 38048045 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE at a dose of 7.4 GBq (200 mCi) every eight weeks for four cycles
Number of subjects: 14
Study 38048045 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Number of subjects: 14
Study 38048133 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretic
Number of subjects: 32804
Study 38048133 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blocker (CCB)
Number of subjects: 32804
Study 38048133 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme (ACE) inhibitor
Number of subjects: 32804
Study 38048134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol, 50 mg twice daily for up to 96 weeks
Number of subjects: 159
Study 38048134 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1 tablet twice daily for up to 96 weeks
Number of subjects: 159
Study 38048134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 159
Study 38048134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 38048145 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX device)
Number of subjects: 0
Study 38048145 — intervention group
Group type: COMPARATOR
Intervention: Bare Metal Stenting (BMS)
Number of subjects: 0
Study 38048147 — intervention group
Group type: EXPERIMENTAL
Intervention: MyBP program (automated bidirectional text messaging for home blood pressure monitoring)
Number of subjects: 17
Study 38048147 — intervention group
Group type: EXPERIMENTAL
Intervention: MyBP program
Number of subjects: 17
Study 38048188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levothyroxine (30 μg per hour for a minimum of 12 hours)
Number of subjects: 838
Study 38048188 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 838
Study 38048188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levothyroxine
Number of subjects: 838
Study 38048354 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based regional dcCL scales
Number of subjects: 4062
Study 38048354 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based regional dcCL scales with mCERAD cutoff of 1.5
Number of subjects: 4062
Study 38048354 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based regional dcCL scales with mCERAD cutoff of 0.5
Number of subjects: 4062
Study 38048391 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus bortezomib/dexamethasone (D-Vd) or lenalidomide/dexamethasone (D-Rd)
Number of subjects: 0
Study 38048480 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based mindful self-compassion for teens (MSC-T) intervention
Number of subjects: 141
Study 38048480 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (standard of care)
Number of subjects: 141
Study 38048552 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD negativity
Number of subjects: 267
Study 38048552 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors (ISS 3, ≥0.01% CTCs, late MRD negativity)
Number of subjects: 267
Study 38048557 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide
Number of subjects: 306
Study 38048557 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide alone
Number of subjects: 306
Study 38048573 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 12512
Study 38048573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12512
Study 38048694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab monotherapy
Number of subjects: 293
Study 38048694 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 293
Study 38048757 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory support (oxygen only, CPAP, or mechanical ventilation) in term infants
Number of subjects: 205977
Study 38048757 — intervention group
Group type: COMPARATOR
Intervention: Respiratory support (oxygen only, CPAP, or mechanical ventilation) in preterm infants
Number of subjects: 205977
Study 38048786 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat 7.5 mg/kg administered as a 2-h intravenous infusion every 4 weeks until disease progression, unacceptable toxic effects, or withdrawal of consent.
Number of subjects: 178
Study 38048786 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as a 2-h intravenous infusion every 4 weeks until disease progression, unacceptable toxic effects, or withdrawal of consent.
Number of subjects: 178
Study 38048786 — intervention group
Group type: EXPERIMENTAL
Intervention: Imetelstat
Number of subjects: 178
Study 38048786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 38048793 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus standard therapy (cisplatin 50 mg/m2)
Number of subjects: 410
Study 38048793 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (cisplatin 50 mg/m2)
Number of subjects: 410
Study 38048799 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (oral dose of 14,000 IU/week)
Number of subjects: 8348
Study 38048799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8348
Study 38048802 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy with camrelizumab (one cycle of priming doublet chemotherapy at 75-80 mg/m2)
Number of subjects: 85
Study 38048802 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-immunotherapy with camrelizumab
Number of subjects: 85
Study 38048882 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-POT technique
Number of subjects: 500
Study 38048986 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearsight™ system (non-invasive monitoring)
Number of subjects: 152
Study 38048986 — intervention group
Group type: EXPERIMENTAL
Intervention: PI ≤ 0.85%
Number of subjects: 152
Study 38048986 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT > 4 s
Number of subjects: 152
Study 38048986 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hand edema
Number of subjects: 152
Study 38048986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac arrhythmia
Number of subjects: 152
Study 38049159 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls Decision Rule (no head CT required)
Number of subjects: 4308
Study 38049159 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of clinically important intracranial bleeding
Number of subjects: 4308
Study 38049197 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 0.5 mg/kg intravenously (IV) twice daily (b.i.d)
Number of subjects: 6
Study 38049523 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial injection of poly(I:C)
Number of subjects: 27
Study 38049586 — intervention group
Group type: EXPERIMENTAL
Intervention: CD138-low/CD27-neg immunophenotypic profile
Number of subjects: 1389
Study 38049586 — intervention group
Group type: EXPERIMENTAL
Intervention: CD138-low/CD27-neg pattern
Number of subjects: 1389
Study 38049620 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation within the central lateral (CL) nucleus of the thalamus and the associated medial dorsal tegmental (CL/DTTm) tract.
Number of subjects: 6
Study 38049620 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation within the CL/DTTm tract (surgery with electrode placement guided by imaging).
Number of subjects: 6
Study 38049622 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 399
Study 38049622 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide alone (placebo group)
Number of subjects: 399
Study 38049621 — intervention group
Group type: COMPARATOR
Intervention: Bivalent vaccine
Number of subjects: 2275
Study 38049621 — intervention group
Group type: COMPARATOR
Intervention: Nonavalent vaccine
Number of subjects: 2275
Study 38049621 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2275
Study 38049713 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT)
Number of subjects: 100
Study 38049713 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluid therapy
Number of subjects: 100
Study 38049783 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-methylation profiling on liquid biopsies
Number of subjects: 75
Study 38049783 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation therapy (CRT)
Number of subjects: 75
Study 38049806 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density transcranial direct current stimulation (HD-tDCS) for 20 minutes at up to 0.63 mA, applied over ipsilesional DLPFC, contralesional cerebellum, or combined DLPFC + contralesional cerebellum.
Number of subjects: 0
Study 38049806 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS intervention.
Number of subjects: 0
Study 38049905 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional physiotherapy
Number of subjects: 70
Study 38049905 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 70
Study 38049955 — intervention group
Group type: EXPERIMENTAL
Intervention: EDV add-on treatment to TAU (intravenous infusion with 30 mg of EDV twice per day)
Number of subjects: 122
Study 38049955 — intervention group
Group type: EXPERIMENTAL
Intervention: NGF add-on treatment to TAU (intramuscular injection of 20 μg of NGF per day)
Number of subjects: 122
Study 38049955 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU: a combination of intramuscular injections of thiamine, intravenous infusions of other B vitamins with vitamin C and oral medication with vitamin E per day)
Number of subjects: 122
Study 38049955 — intervention group
Group type: EXPERIMENTAL
Intervention: EDV add-on treatment to TAU
Number of subjects: 122
Study 38050037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg once a week
Number of subjects: 0
Study 38050037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38050056 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate (RL)
Number of subjects: 52
Study 38050056 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 52
Study 38050066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate and taurursodiol (PB and TURSO)
Number of subjects: 0
Study 38050090 — intervention group
Group type: EXPERIMENTAL
Intervention: NeVa device
Number of subjects: 139
Study 38050127 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38050181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet-flavoured cigarillos
Number of subjects: 0
Study 38050187 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom screening programme for CTEPH detection
Number of subjects: 646
Study 38050187 — intervention group
Group type: COMPARATOR
Intervention: Routine care (before symptom screening protocol)
Number of subjects: 646
Study 38050187 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic probability of pulmonary hypertension (PH) after symptom screening
Number of subjects: 646
Study 38050584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Steps intervention
Number of subjects: 19
Study 38050584 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 19
Study 38050693 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs
Number of subjects: 489
Study 38050693 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs (biologic-naive)
Number of subjects: 489
Study 38050693 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARDs (biologic-experienced)
Number of subjects: 489
Study 38050737 — intervention group
Group type: EXPERIMENTAL
Intervention: CA19-9-normal subgroup (≤37 U/mL)
Number of subjects: 1558
Study 38050737 — intervention group
Group type: COMPARATOR
Intervention: CA19-9-high subgroup (>37 U/mL)
Number of subjects: 1558
Study 38050737 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose control in pancreatic cancer animal models
Number of subjects: 1558
Study 38050737 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose control in clinical trial (NCT05306028)
Number of subjects: 1558
Study 38050854 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids given orally
Number of subjects: 787
Study 38050854 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 787
Study 38050854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787